TY  - JOUR
AU  - Merz, Maximilian
AU  - Ritsch, Judith
AU  - Kunz, Christina
AU  - Wagner, Barbara
AU  - Sauer, Sandra
AU  - Hose, Dirk
AU  - Moehler, Thomas
AU  - Delorme, Stefan
AU  - Goldschmidt, Hartmut
AU  - Zechmann, Christian
AU  - Hillengass, Jens
TI  - Dynamic contrast-enhanced magnetic resonance imaging for assessment of antiangiogenic treatment effects in multiple myeloma.
JO  - Clinical cancer research
VL  - 21
IS  - 1
SN  - 1557-3265
CY  - Philadelphia, Pa. [u.a.]
PB  - AACR
M1  - DKFZ-2017-03150
SP  - 106 - 112
PY  - 2015
AB  - To noninvasively assess bone marrow microcirculation before and after therapy in patients with newly diagnosed multiple myeloma with dynamic contrast-enhanced MRI (DCE-MRI).Ninety-six patients received DCE-MRI before and after primary treatment for newly diagnosed multiple myeloma. For the 91 evaluable patients, treatment consisted of high-dose therapy (HDT) with autologous stem cell transplantation (ASCT) in 82 patients and chemotherapy without ASCT in 9 patients. In addition, 33 healthy volunteers were imaged as the control group. Analysis of DCE-MRI was performed according to the two-compartment model by Brix to quantify amplitude A (associated with blood volume) and exchange rate constant kep (reflecting vessel permeability and perfusion).Nonresponders showed significantly higher A-values before the start of therapy compared with responders (P = 0.02). In both responders and nonresponders to therapy, A-values dropped significantly (P = 0.004 and <0.001, respectively) after primary therapy, whereas lower values for kep were found only in responders (P < 0.001). Depth of remission was significantly correlated to decreased bone marrow microcirculation: Patients in near complete response (nCR) or complete remission (CR) after treatment showed significantly lower values for A compared with patients not achieving nCR+CR. The application of HDT or novel agents had no significant effect on DCE-MRI parameters after therapy, although patients treated with novel agents more often achieved nCR+CR (42
KW  - Angiogenesis Inhibitors (NLM Chemicals)
LB  - PUB:(DE-HGF)16
C6  - pmid:25351744
DO  - DOI:10.1158/1078-0432.CCR-14-1029
UR  - https://inrepo02.dkfz.de/record/127124
ER  -